SBIR/STTR Research Award

New small molecule inhibitors of arenaviruses

Award identifier 3a2c8df1b454ba55aa3575709edaaebeb0ee7dc8bfd6c4d899a837692fe21954Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$598,297

Program and phase

STTR · Phase I

Award year

2014

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
MICROBIOTIX, INC.
Proposal award date
2014-02-15
Contract end date
2017-01-31
UEI
SCNKBDM341T1
Solicitation number
PA10-124
Topic code
R

Research abstract

DESCRIPTION provided by applicant Lassa fever virus LASV and Machupo virus MACV are hemorrhagic fever arenaviruses which are classified as Category A Agents Currently there are no licensed LASV or MACV vaccines and LASV MACV therapy is limited to use of the nucleoside analog ribavirin which is only partially effective and associated with significant side effects The impact of arenaviruses on public health and biodefense readiness coupled with limited treatment options to combat arenavirus infections underscore the importance of developing novel and effective strategies to combat arenaviruses especially LASV and MACV New small molecule inhibitors would be of paramount importance for use during arenaviral outbreaks or bioterrorist attacks This application defines a plan to develop potent small molecule inhibitors which block entry of LASV and MACV Entry of LASV and MACV into the hosts is mediated by a single viral glycoprotein GP which is considered one of the major therapeutic targets GP consists of three subunits GP GP and a stable signal peptide SSP GP is responsible for receptor binding and host tropism while GP mediates viral cell membrane fusion and viral entry We have used an HTS protocol targeting GP mediated viral entry to screen a small molecule library and we have identified compounds that inhibit entry of LASV and MACV IC values M These hit compounds exhibit selectivity for arenavirus entry The overall objective of this Phase I application is to develop these inhibitors as potentia antiviral therapeutics This application will focus on the following three specific aims Synthesize structurally diverse analogs of the anti arenavirus MBX hit series based on structure activity relationships SARs to improve potency and selectivity Select LASV MACV inhibitors with in vitro ADME properties suitable for i v and oral dosing Validate the lead inhibitor candidates in the infectious assays and investigate the mechanism of action MOA of the LASV MACV inhibitors PUBLIC HEALTH RELEVANCE This project is to discover and develop small molecule entry inhibitors for arenaviruses The proposed research will help to develop potential antiviral therapeutics

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Research funding history

85 SBIR/STTR records share this UEI (2001–2025). Reported award amounts total $75,824,388. Reported amounts are not federal obligations.

Phases: Phase I, Phase II, Phase II – Direct to Phase II

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.